Uric acid measurement improves prediction of cardiovascular mortality in later life

Journal of the American Geriatrics Society

Volumn 61, Issue 3, 2013, Pages 319-326

  Dutta, Ambarish ^a   Henley, William ^a   Pilling, Luke C ^a   Wallace, Robert B ^b   Melzer, David ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

cardiovascular disease; Framingham Cardiovascular Risk Score; risk factors; survival analysis; uric acid

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; URIC ACID;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; HUMAN EXPERIMENT; LIFESPAN; MEASUREMENT; OBESITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SMOKING; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; IOWA; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; UNITED STATES; URIC ACID;

EID: 84875231383     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12149     Document Type: Article

References (50)

1. Gorina Y, Hoyert D, Lentzner H, et al. Trends in Causes of Death among Older Persons in the United States. Aging Trends, No 6. Hyattsville, MD: National Center for Health Statistics, 2006.
2. Yazdanyar A, Newman AB,. The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-577.
3. Stork S, Feelders RA, van den Beld AW, et al. Prediction of mortality risk in the elderly. Am J Med 2006; 119 (6): 519-525.
4. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ 2009; 338: a3083.
5. van Bemmel T, Gussekloo J, Westendorp RGJ, et al. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. J Hypertens 2006; 24: 287-292.
6. Troseid M, Seljeflot I, Hjerkinn EM, et al. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome synergistic effect of inflammation and hyperglycemia. Diabetes Care 2009; 32 (3): 486-492.
7. Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: A prospective 21-year follow-up study. Int J Cardiol 2008; 125: 232-239.
8. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: A prospective long-term study of 83,683 Austrian men. Clin Chem 2008; 54: 273-284.
9. Wu YQ, Li J, Xu YX, et al. Predictive value of serum uric acid on cardiovascular disease and all-cause mortality in urban Chinese patients. Chin Med J (Engl) 2010; 123: 1387-1391.
10. Bos MJ, Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam Study. Stroke 2006; 37: 1503-1507.
11. Ong G, Davis WA, Davis TM,. Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: The Fremantle Diabetes Study. Diabetologia 2010; 53: 1288-1294.
12. Niizeki T, Takeishi Y, Arimoto T, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 2006; 47: 219-228.
13. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
14. Huang CC, Peng MC, Tsai WC, et al. The serum uric acid and related cardiovascular risk factors in south Taiwan. Southeast Asian J Trop Med Public Health 2005; 36: 259-264.
15. Wannamethee SG,. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 2005; 11: 4125-4132.
16. Cornoni-Huntley J, Ostfeld AM, Taylor JO, et al. Established populations for epidemiologic studies of the elderly: Study design and methodology. Aging (Milano) 1993; 5: 27-37.
17. National Center for Health and Statistics (U.S.). Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: Programs and collection procedures. Vital Health Stat 1 1994; 32: 1-407.
18. Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 2006; 19: 208-213.
19. Lin KC, Lin HY, Chou P,. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27: 1045-1050.
20. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-1110.
21. Leask RG, Andrews GR, Caird FI,. Normal values for sixteen blood constituents in the elderly. Age Ageing 1973; 2: 14-23.
22. Kelso T,. Laboratory values in the elderly. Are they different?. Emerg Med Clin North Am 1990; 8: 241-254.
23. Cook DG, Shaper AG, Macfarlane PW,. Using the WHO (Rose) angina questionnaire in cardiovascular epidemiology. Int J Epidemiol 1989; 18: 607-613.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
25. Therneau TM, Grambsch PM,. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
26. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008; 117: 743-753.
27. Pencina MJ, D'Agostino RB, Steyerberg EW,. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30: 11-21.
28. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
29. van der Velde M, Bakker SJL, de Jong PE, et al. Influence of age and measure of eGFR on the association between renal function and cardiovascular events. Clin J Am Soc Nephrol 2010; 5: 2053-20590.
30. Lai SW, Tan CK, Ng KCCP,. Epidemiology of hyperuricemia in the elderly. Yale J Biol Med 2001; 74: 151-157.
31. Kanellis J, Feig DI, Johnson RJ,. Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed. Nephrology (Carlton) 2004; 9: 394-399.
32. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
33. Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced gfr on cardiovascular morbidity: A historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis 2011; 58: 398-408.
34. Fang J, Alderman MH,. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
35. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008; 58: 623-630.
36. Hu P, Seeman TE, Harris TB, et al. Is serum uric acid level associated with all-cause mortality in high-functioning older persons: MacArthur Studies of Successful Aging? J Am Geriatr Soc 2001; 49: 1679-1684.
37. Stöckl D, Döring A, Thorand B, et al. Reproductive factors and serum uric acid levels in females from the general population: The KORA F4 study. PLoS ONE 2012; 7: e32668.
38. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141: 637-644.
39. Mazza A, Zamboni S, Rizzato E, et al. Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The Cardiovascular STudy in the ELderly (CASTEL). Acta Diabetol 2007; 44: 99-105.
40. McDermott MM,. The international pandemic of chronic cardiovascular disease. JAMA 2007; 297: 1253-1255.
41. Ali R, Alexander KP,. Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. Am J Geriatr Pharmacother 2007; 5: 52-63.
42. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: A hierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51: 37-45.
43. Kannel WB,. Cardiovascular disease preventive measures for the older patient: An epidemiologic perspective. Am J Geriatr Cardiol 2006; 15: 382-388.
44. Andrawes WF, Bussy C, Belmin J,. Prevention of cardiovascular events in elderly people. Drugs Aging 2005; 22: 859-876.
45. Alderman M, Aiyer KJ,. Uric acid: Role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369-379.
46. Waring WS,. Uric acid: An important antioxidant in acute ischaemic stroke. QJM 2002; 95: 691-693.
47. Suliman ME, Johnson RJ, Garcia-Lopez E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 00: 761-771.
48. Bergmann MM, Byers T, Freedman DS, et al. Validity of self-reported diagnoses leading to hospitalization: A comparison of self-reports with hospital records in a prospective study of American adults. Am J Epidemiol 1998; 147: 969-977.
49. Fisher GG, Faul JD, Weir DR, et al. Documentation of Chronic Disease Measures in the Health and Retirement Study (HRS/AHEAD). Ann Arbor: Survey Research Center, University of Michigan, 2005.
50. Jurek AM, Greenland S, Maldonado G, et al. Proper interpretation of non-differential misclassification effects: Expectations vs observations. Int J Epidemiol 2005; 34: 680-687.